PsychoGenics is redefining neuropsychiatric drug discovery through industrialized behavioral testing. By generating and analyzing vast amounts of data on how animals respond to compounds ...

PsychoGenics has developed a pioneering approach to neuropsychiatric drug discovery using behavioral assays combined with machine learning to create a high-throughput behavioral screening technology.

U.S. government researchers have found that a widely prescribed asthma drug originally sold by Merck & Co may be linked to ...

New data collected by the FDA has found that montelukast can bind to brain cells, which may explain the risk of mental health adverse effects linked to its use.

The link between lupus and bipolar disorder is complex and can lead to misdiagnosis. Learn how to recognize the symptoms of ...

Boston-based Seaport said the money would support a pipeline of improved neuropsychiatric drug candidates led by SPT-300, an oral prodrug of allopregnanolone that is being studied for major ...

"It means that those drugs are homing in on particular cell ... the findings could help facilitate precision-medicine ...

Waltham, Massachusetts-based Blue Oak – led by neurobiologist and former Eli Lilly and Sunovion executive Tom Large – will work with Exscientia on new classes of neuropsychiatric drugs ...

ITI-333 is a small molecule commercialized by Intra-Cellular Therapies, with a leading Phase I program in Opium (Opioid) Addiction.